Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021.
Markov model
basal cell carcinoma
cost-of-illness
healthcare costs
keratinocyte cancer
melanoma
squamous cell carcinoma
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
08 03 2022
08 03 2022
Historique:
received:
09
01
2022
revised:
22
02
2022
accepted:
02
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Australia and Aotearoa New Zealand have the highest incidence of melanoma and KC in the world. We undertook a cost-of-illness analysis using Markov decision-analytic models separately for melanoma and keratinocyte skin cancer (KC) for each country. Using clinical pathways, the probabilities and unit costs of each health service and medicine for skin cancer management were applied. We estimated mean costs and 95% uncertainty intervals (95% UI) using Monte Carlo simulation. In Australia, the mean first-year costs of melanoma per patient ranged from AU$644 (95%UI: $642, $647) for melanoma
Identifiants
pubmed: 35328865
pii: ijerph19063178
doi: 10.3390/ijerph19063178
pmc: PMC8948716
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Acta Derm Venereol. 2008;88(5):467-73
pubmed: 18779884
Ann Surg Oncol. 2014 Jul;21(7):2245-51
pubmed: 24748128
Int J Environ Res Public Health. 2020 Apr 20;17(8):
pubmed: 32326074
Prev Med. 2009 Nov;49(5):449-53
pubmed: 19747936
Med Care. 2015 Apr;53(4):302-9
pubmed: 25749656
BMC Public Health. 2015 Sep 23;15:952
pubmed: 26400024
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
N Engl J Med. 2020 Sep 17;383(12):1139-1148
pubmed: 32877599
Value Health. 2012 Mar-Apr;15(2):261-8
pubmed: 22433757
J Clin Oncol. 2020 Nov 20;38(33):3937-3946
pubmed: 32997575
Int J Cancer. 2018 Apr 15;142(8):1528-1535
pubmed: 29105744
Australas J Dermatol. 2015 Feb;56(1):70-6
pubmed: 25196191
Australas J Dermatol. 2008 Feb;49(1):12-5
pubmed: 18186839
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
JAMA Dermatol. 2019 Oct 1;155(10):1167-1174
pubmed: 31290958
BMJ Open. 2020 Feb 27;10(2):e032636
pubmed: 32111612
Aust N Z J Public Health. 2015 Oct;39(5):471-6
pubmed: 26437734
Appl Health Econ Health Policy. 2017 Dec;15(6):805-816
pubmed: 28756584
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
J Invest Dermatol. 2009 Dec;129(12):2766-71
pubmed: 19536149
Pharmacoeconomics. 2007;25(1):3-6
pubmed: 17192114
Int J Epidemiol. 2012 Aug;41(4):929-929i
pubmed: 22933644
Arch Dermatol. 2009 Nov;145(11):1253-60
pubmed: 19917954
Eur J Cancer. 2021 Sep;154:111-119
pubmed: 34256280
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Int J Cancer. 2015 Feb 1;136(3):603-9
pubmed: 24806428
Health Econ Rev. 2018 Oct 31;8(1):28
pubmed: 30382489
Eur J Cancer Prev. 2015 Mar;24(2):141-9
pubmed: 25089375
Med J Aust. 2017 Oct 16;207(8):339-343
pubmed: 29020905
Int J Technol Assess Health Care. 2013 Apr;29(2):117-22
pubmed: 23587340
Cancer Causes Control. 2006 Feb;17(1):21-7
pubmed: 16411049
Australas J Dermatol. 2012 May;53(2):112-7
pubmed: 22571558
Med J Aust. 2007 Aug 20;187(4):210-4
pubmed: 17708722
J Public Health (Oxf). 2014 Mar;36(1):140-8
pubmed: 23554510
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153